This review summarizes the pharmacology and contemporary clinical indications for intravenous antiplatelet therapies, highlighting cangrelor's rapid anti-ischemic benefit without increased major bleeding during PCI.
receptor antagonist. In a large-scale regulatory trial, cangrelor administration during PCI allowed for rapid, potent and rapidly reversible inhibition of platelet aggregation, with an anti-ischemic benefit and no increase in major bleeding. This article aims to provide an overview of general pharmacology, supporting evidence and current status of intravenous antiplatelet therapies (GPIs and cangrelor), with a focus on contemporary indications for their clinical use.
Capodanno et al. (Tue,) studied this question.